The Transition From Adjuvant Trials to New Adjuvate Trials in Patients With High Risk Breast Cancer

Dr. Esserman: The future really is about tailoring care, less for the great responders and more shots on the goal for people who are not having optimal response. Discussed future directions for the Phase 2 I-Spy 2 trial in patients with high risk breast cancer. And a framework for how we get 90% of people to complete response without standard chemotherapy.